\
&
Contact us
\
&
Contact us
Published on | 8 months ago
Programmes Enhancing EU R&IThe GENDERACTIONplus project wrote an open letter to Ekaterina Zaharieva, European Commissioner-Designate for Start-ups, Research and Innovation, to stress the importance to continue working to expand gender equality policies and ensure that these policies incorporate inclusivity and intersectional perspectives, including maintaining Gender Equality Plans as an eligibility criterion for accessing EU research funding under Horizon Europe, a crucial policy for advancing gender equality in research and higher education institutions.
The open letter can be signed (scroll down below letter) as an individual, with the option to remain anonymous or without affiliation. It is also possible to leave a short comment that could be used for an upcoming social media campaign. Up-to-date the letter has 600 signatories.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
